Fulvestrant plus DNA damage drugs after CDK4/6 treatment failure
Treatments studied
Part of Cancer clinical trials.
This Phase 2 trial studies whether combining fulvestrant with medicines that block DNA repair can help treat HR+/HER2- metastatic or inoperable breast cancer that has progressed after endocrine therapy plus a CDK4/6 inhibitor. It also aims to check the safety of this combination and see if it can control the cancer for longer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You can sign an informed consent form and agree to follow the study rules
- You are 19 years or older with HR-positive, HER2-negative metastatic or inoperable breast cancer
- Your cancer has grown or worsened after endocrine therapy and a CDK4/6 inhibitor
- Your blood counts, liver, and kidney tests are within required ranges (from tests done within 28 days of starting)
- Your heart status and general health are good enough (ECOG performance status 0–1, and life expectancy at least 16 weeks)
- Your disease has at least one tumor spot that can be measured by CT or MRI at the start
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three drugs (chidamide, an angiogenesis inhibitor, and fulvestrant) for advanced hormone-positive, HER2-negative breast cancer that has worsened after CDK4/6 inhibitor treatment. The goal is to see if this combination can slow cancer growth for a longer time.
This Phase 2 study tests a genetically guided treatment plan for ER-positive breast cancer that has progressed after CDK4/6 therapy. It may help by matching treatment to tumor genetic changes.
This Phase 2 trial tests an investigational “SNF platform” treatment for advanced ER+ (estrogen-receptor positive) and HER2− breast cancer in people who already tried CDK4/6 inhibitor therapy. It may help shrink tumors and improve outcomes for cancers that have come back or spread.
This Phase 2 study tests whether combining a PARP inhibitor with a CDK4/6 inhibitor and hormone (endocrine) therapy can help people with advanced HR-positive, HER2-negative breast cancer. It’s for certain patients who have not yet had chemotherapy or targeted therapy for metastatic disease.
This trial tests a new study medicine (PF-07248144) combined with fulvestrant in people with a certain type of advanced breast cancer (HR-positive, HER2-negative) that has worsened after previous treatments. It may be an option if you've already tried a CDK4/6 inhibitor and endocrine therapy.
This trial tests a new pill (M1774) combined with a hormone therapy called fulvestrant for people with advanced hormone-receptor-positive, HER2-negative breast cancer that has stopped responding to standard hormone therapy and CDK4/6 inhibitors. The study focuses on people with certain genetic markers in their tumor, hoping the combination will work better than current options.
Hear when a new Advanced Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.